<DOC>
	<DOCNO>NCT01519778</DOCNO>
	<brief_summary>Characterization safety profile TR-701 Free Acid ( FA ) patient major cutaneous abscess cellulitis/erysipelas .</brief_summary>
	<brief_title>A Phase 2 Safety Exploratory Skin Lesion Measurement TR-701 FA Study</brief_title>
	<detailed_description>This open-label , multicenter study oral TR-701 FA 200 mg daily 6 day treatment major cutaneous abscess cellulitis/erysipelas patient 18 year age old . This study design characterize safety profile gather additional lesion measurement data TR-701 FA patient major cutaneous abscess cellulitis/erysipelas .</detailed_description>
	<mesh_term>Abscess</mesh_term>
	<mesh_term>Cellulitis</mesh_term>
	<mesh_term>Erysipelas</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>Male female patient â‰¥ 18 year age Suspected documented grampositive infection baseline Gram stain culture . Cellulitis/erysipelas major cutaneous abscess Screening Postsurgical open wound infection Severe sepsis septic shock Uncomplicated skin skin structure infection furuncle , minor abscess ( &lt; 75 cm2 area suppuration surround cellulitis/erythema ) , impetiginous lesion Infections associate , close proximity , prosthetic device Known bacteremia osteomyelitis time screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>